ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.…
Abivax to Participate in Upcoming Fall Investor Conferences
ABIVAX (NASDAQ: ABVX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 98 employees.
The shares were at 73.20 USD on 20 November 2026, down 29.2% over 52 weeks. Its 52-week range is 62.97 USD to 148.83 USD: the price is 50.8% below the high and 16.2% above the low.
Its market capitalisation is 6.41B USD.
ABIVAX reports return on equity of -73.8% and revenue down 6.8% year over year.
It holds more cash than debt, a net cash position of 401.17M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 12 analysts cover the stock; their mean price target of 163.58 USD is 123.5% above the current price. The next earnings report is expected on 22 March 2027.